Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 7/20 | 0.47 |
| ▸ | FLT4 | P35916 | 7/20 | 0.47 |
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8277157 | 0.85 | KDM1A (0.49) | LMNA | |
| SCHEMBL692474 | 0.83 | BCL2L1 (0.47) | BCL2L1MCL1MAPTFLT1FLT4 | |
| SCHEMBL692997 | 0.82 | BCL2L1 (0.53) | BCL2L1MCL1MAPTFLT1FLT4 | |
| SCHEMBL692561 | 0.82 | BCL2L1 (0.51) | BCL2L1MCL1MAPTFLT1FLT4 | |
| SCHEMBL693063 | 0.79 | BCL2L1 (0.46) | BCL2L1MCL1MAPTFLT1FLT4 | |
| SCHEMBL692988 | 0.78 | CTRC (0.46) | ALDH1A1LMNATP53 | |
| SCHEMBL692973 | 0.76 | MEN1 (0.47) | BCL2L1MCL1MAPTLMNATP53 | |
| SCHEMBL9176789 | 0.75 | FLT1 (0.84) | MAPTFLT1FLT4KDRALDH1A1 | |
| SCHEMBL789891 | 0.75 | FLT1 (0.84) | MAPTFLT1FLT4KDRALDH1A1 | |
| SCHEMBL692183 | 0.72 | TP53 (0.52) | BCL2L1MCL1MAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560654-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | claimed |
| EP-2421368-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | claimed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | claimed |
| WO-2011133600-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | claimed |
| WO-2010123822-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2560654-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-24 | — | — | US | disclosed |
| EP-2421368-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| WO-2011133600-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010123822-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129858-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES | CFTR, PKD1, PKD2 | BCL2L1 2378/4885MCL1 3410/4885MAPT 4875/4885 |
| US-20110288093-A1 | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives | SCN1A, CLIC1, CLCN2 | BCL2L1 2945/4885MCL1 1854/4885MAPT 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.